2011
DOI: 10.1016/j.jaad.2011.02.009
|View full text |Cite
|
Sign up to set email alerts
|

Facial Soft-Tissue Fillers conference: Assessing the State of the Science

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
9
0

Year Published

2012
2012
2016
2016

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 19 publications
(9 citation statements)
references
References 50 publications
0
9
0
Order By: Relevance
“…and Prevelle Silk (Mentor Corporation, Santa Barbara, Calif.). 19,[33][34][35][36][37][38][39] Small aliquots of HA may be injected in the face, neck, or décolletée over a series of treatment sessions to improve skin hydration and texture. 26 Hydrelle lasts for about 12 months, but its use has been limited by anecdotal reports of severe inflammatory reactions-painful swelling and blistering-in patients with no known allergies.…”
Section: Hyaluronic Acidmentioning
confidence: 99%
“…and Prevelle Silk (Mentor Corporation, Santa Barbara, Calif.). 19,[33][34][35][36][37][38][39] Small aliquots of HA may be injected in the face, neck, or décolletée over a series of treatment sessions to improve skin hydration and texture. 26 Hydrelle lasts for about 12 months, but its use has been limited by anecdotal reports of severe inflammatory reactions-painful swelling and blistering-in patients with no known allergies.…”
Section: Hyaluronic Acidmentioning
confidence: 99%
“…The mechanism of action involves induction of a subclinical inflammatory response that stimulates fibroblast proliferation and collagen formation, ultimately leading to a progressive increase in volume of the dermis and subcutaneous tissues. 2 Late-onset immune-mediated adverse effects associated with the use of poly- l -lactic acid can appear years after the initial injection with reported range of 6 to 60 months. 3 These effects include inflammatory nodules, papules, and edema.…”
Section: Introductionmentioning
confidence: 99%
“…The FDA received 930 post-marked reports of adverse event from 2003 through 2008, of which 823 were deemed severe and 638 required medical treatment and follow-up. The most frequently reported injection site was the nasolabial fold (35.6 %); however, the majority of reported AEs occurred in sites other than the nasolabial fold, such as lips, periorbital region, and perioral region [3].…”
Section: Introductionmentioning
confidence: 99%